ALT Altimmune Inc.

2.12
+0.02  (+1%)
Previous Close 2.1
Open 2.1
Price To Book 0.58
Market Cap 32,508,893
Shares 15,338,001
Volume 32,316
Short Ratio
Av. Daily Volume 188,258

NewsSee all news

  1. Altimmune Appoints M. Scott Harris, M.D. as Chief Medical Officer

    GAITHERSBURG, Md., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced it has appointed M. Scott Harris, M.D. as Chief Medical Officer. Dr.

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial planned for 2020.
HepTCell
Hepatitis B
Phase 2 additional data released March 19, 2019 noted all patients remained seroprotected.
NasoVAX
Flu vaccine
Phase 1b trial to be initiated in 2019.
NASOSHIELD
Anthrax
IND to be filed in 2020 with Phase 1 data due 2021.
ALT-801
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. Altimmune Appoints M. Scott Harris, M.D. as Chief Medical Officer

    GAITHERSBURG, Md., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced it has appointed M. Scott Harris, M.D. as Chief Medical Officer. Dr.